Skip to main content

Outreach News

The unexpected form of a protein tied to cancer could unlock new treatments

ICMAB researchers have simulated the behaviour of a molecule whose malfunction is linked to cancer and for which no drugs exist. The results show that the shape we had studied is not the most common one, opening the gate to new research lines.

The previously-known scissor shape of MAX and MYC (left) and the recently found more probable shapes (right) | ICMAB CSIC
MAX and MYC are two proteins that, when combined, are responsible for regulating cell reproduction; however, their overexcitement is highly linked to tumour genesis. Their malfunction being key in around 70% of tumours, together with their apparent simple shape, made this pair a perfect target for new anti-cancer drugs. However, they remain undrugged to this day.

Researchers from the Institute of Materials Science of Barcelona (ICMAB-CSIC) Huixia Lu and Jordi Faraudo, together with Jordi Martí (UPC), have discovered that MAX, when studied on its own, adopts shapes very different from the rigid forms seen in crystallography. “For many years, we had thought the scissor shape of this couple we saw via X-ray was the shape in real-world conditions. Now we see it is not”, says the senior researcher Jordi Faraudo. The idea for drug researchers is to suppress either of the two molecules before they combine and become overexpressed, thereby reducing cancer growth. This study suggests that the shapes they were aiming for may not be accurate.

Until now, most studies relied on X-ray crystallography, which showed MYC and MAX in a rigid scissor-like shape. But proteins in living cells are not static. Using advanced molecular simulations, the team explored how MAX behaves in aqueous solution and found that it does not stick to its crystallised structure. Instead, it adopts several alternative shapes that require much less energy and are therefore much more likely to occur in real biological conditions.

This discovery changes the game, says Faraudo: “the most optimal way to combat its overexpression is another one that targets other shapes.” To which Huixia Lu adds: “This might help explain why MAX has remained difficult to target with drugs since its first structure was solved more than 30 years ago.”

Graphical abstract of the investigation | Lu et al., available in ACS

A new hope for drug design

Among the newly identified shapes, three show compatibility with an existing drug (named 10058-F4). This opens the door to designing drugs that target MAX directly or prevent its interaction with MYC, potentially impacting many types of cancer. “Methods like in silico drug design and machine-learning-accelerated drug screening are anticipated to uncover compounds that directly bind MAX,” says Huixia Lu, “this facilitates MYC degradation and reduces tumour growth.”

A question remains

This finding opens the gate to a new question: Does the same happen to other clusters? As Faraudo puts it: “This is a very simple-shaped protein. If this mismatch between X-ray and reality happens with MAX, it must be happening with many more molecules!”

Reference

Probing the Structural Dynamics of the Unbound MAX Protein: Insights from Well-Tempered Metadynamics
Lu, H., Marti, J., & Faraudo, J.
Journal Of Chemical Information And Modeling. 2025.
DOI: 10.1021/acs.jcim.5c02155

More news

Daniel Rodríguez Urbano
Daniel Rodríguez Urbano
16 January 2026